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Abstract 28 
Context: The pathophysiological mechanism of increased fractures in young adults with 29 
Type 1 Diabetes Mellitus (T1DM) is unclear. 30 
Objective: Case:control study of trabecular bone microarchitecture and vertebral marrow 31 
adiposity in young women with T1DM. 32 
Patients & Settings: 30 women with T1DM with a median (range) age of 22.0yrs (16.9, 33 
36.1) attending one outpatient clinic with a median age at diagnosis of 9.7yrs (0.46, 14.8) 34 
were compared to 28 age-matched healthy women who acted as controls.  35 
Methods & Main Outcome Measures: Measurements included MRI-based assessment 36 
of proximal tibial bone volume/total volume (appBV/TV), trabecular separation 37 
(appTb.Sp), vertebral bone marrow adiposity (BMA) and abdominal adipose tissue and 38 
biochemical markers of GH/IGF-1 axis (IGF-1, IGFBP3, ALS) and bone turnover. 39 
Results: Median appBV/TV in cases and controls was 0.3 (0.22, 0.37) and 0.33 (0.26, 40 
0.4), respectively (p=0.018) and median appTb.Sp in T1DM was 2.59 (2.24, 3.38) and 41 
2.32 (2.03, 2.97), respectively (p=0.012). The median appBV/TV was 0.28 (0.22, 0.33) in 42 
those cases with retinopathy (n,15) compared to 0.33 (0.25, 0.37) in those without 43 
retinopathy (p=0.02). Although median visceral adipose tissue in cases was higher than in 44 
controls at 5,733mm3 (2030, 11,144) and 3,460mm3 (1,808, 6,832), respectively 45 
(p=0.012), there was no difference in median BMA which was 31.1% (9.9, 59.9) and 46 
26.3% (8.5, 49.8) in cases and controls, respectively (p=0.2). Serum IGF-1 and ALS were 47 
also lower in cases and the latter showed an inverse association to appTbSp (r=-0.30, 48 
p=0.04). 49 
Conclusion: Detailed MRI studies in young women with childhood-onset T1DM have 50 
shown clear deficits in trabecular microarchitecture of the tibia. Underlying 51 
pathophysiological mechanisms may include a microvasculopathy. 52 
Abstract Word Count - 261 53 
 54 
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Introduction 55 
The risk of hip fractures in those with Type 1 diabetes mellitus (T1DM) is reported to be 56 
7–12 times greater (1, 2) and this increased risk is also evident in young adults (3). The 57 
process of differentiation of mesenchymal stem cells into either adipocytes or osteoblasts 58 
is regulated by a number of growth factors including insulin, oxygen tension and blood 59 
flow within the bone marrow (4, 5). T1DM is also associated with abnormalities of the 60 
growth hormone (GH)/insulin-like growth factor type 1 (IGF-1) axis with biochemical 61 
evidence of GH resistance (6). Growth hormone (GH) and IGF-1 also are important 62 
regulators of bone homeostasis and important for the maintenance of bone mass (7) and 63 
may also influence body composition and bone marrow adiposity (8). Mouse models of 64 
T1DM exhibit increased bone marrow adiposity (BMA), increased adipocyte markers and 65 
increased numbers of lipid-dense adipocytes in the bone marrow (9). Childhood and 66 
adolescence are critical periods for skeletal development (10) and it is possible that those 67 
affected by T1DM at these ages may be especially susceptible.  68 
 69 
On dual energy X-Ray absorptiometry (DXA), adults with T1DM do show a reduction in 70 
bone mineral density (BMD) Z-score, reported in a meta-analysis at -0.22 at the lumbar 71 
spine and -0.37 at the hip (11), but their fracture risk is much higher (1-3,11) than 72 
expected for this modest reduction in BMD. Recent advances in magnetic resonance 73 
(MR) imaging have led to the generation of high resolution 3D images of bone structure 74 
that correlate with other techniques such as computed tomography (12,13). In addition, 75 
MR can quantify the amount of intra-abdominal fat, and MR spectroscopy can also 76 
estimate the fat that is present within the bone marrow (14). There is, therefore, the 77 
potential to combine these MR-based techniques to obtain objective data on bone 78 
microarchitecture and fat content and study these in a condition such as T1DM.  79 
 80 
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With the increased reports of an association between marrow adiposity and bone health 81 
(15), the current study was designed to improve the understanding of the bone pathology 82 
in adults with childhood-onset T1DM by using high resolution MRI and biochemical 83 
markers of GH action and bone turnover. To reduce the confounding effect of sex 84 
hormones, this study targeted young women with T1DM and compared them to a group 85 
of age-matched healthy women. 86 
 87 
 88 
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Research Design & Methods 108 
Subjects 109 
Between July 2012 and July 2013, 61 eligible women between the ages of 20 and 30 110 
years and who were diagnosed before the age of 16 years were approached at one hospital 111 
clinic and from this group, 30 volunteered to participate. In addition, 28 age-matched 112 
healthy control women working at the local university and hospital were also recruited. 113 
Exclusion criteria included the presence of metallic implants and pacemakers, active or 114 
planned pregnancy or lactation, kidney disease, chronic use of drugs that are known to 115 
affect bone health and other chronic diseases that are known to be associated with an 116 
increased risk of fractures. Information on personal health and lifestyle habits, including 117 
cigarette smoking, alcohol consumption, current medication, use of vitamins or calcium, 118 
age at menarche, use of oral contraceptives, hours of weight-bearing physical activity per 119 
week, history of fractures and a family history of early osteoporosis was also collected. 120 
Information on age of diagnosis, disease duration, insulin therapy and presence of 121 
microvascular complications was obtained from the case records. A glycosylated 122 
hemoglobin (HbA1c) measurement within a two-week period of the scan visit was used 123 
as current HbA1c. The study protocol was approved by the national research ethics 124 
service and all participants provided written informed consent. 125 
 126 
Biochemical Markers of Bone Metabolism, Adiposity & GH/IGF-1 Axis   127 
In 25 cases and 24 control participants, non-fasting blood samples were collected, 128 
centrifuged and the supernatant stored at -800C. Sample collection was standardised with 129 
collection performed in the afternoon to coincide with the clinic visit. Plasma total 130 
osteocalcin (OC) and serum bone-specific alkaline phosphatase (BAP), were analyzed by 131 
ELISA to assess bone formation (Immunodiagnostic systems, Boldon, Tyne and Wear, 132 
United Kingdom). Plasma undercarboxylated osteocalcin (uOC) was used to assess the 133 
inactive form of osteocalcin (Cusabio Life Science, Wuhan, P.R. China) and plasma C 134 
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terminal telopeptide of Type I collagen (CTX) was measured by ELISA to assess bone 135 
resorption (Immunodiagnostic systems, Boldon, Tyne and Wear, United Kingdom). The 136 
intra-assay variation for OC, uOC, BAP and CTX was 5.3%, 13.2%, 0.8% and 3.8%, 137 
respectively. Plasma leptin, IGF-I and its binding proteins, IGFBP3, and the acid labile 138 
subunit (ALS) were also determined, using ELISA (Mediagnost GmbH, Reutlingen, 139 
Germany). Intra-assay variabilities were 6.1%, 0.6%, 4.1% and 3.4%, respectively. 25-140 
Hydroxy vitamin D (25OHD) concentration was measured by a radioimmunoassay 141 
(Immunodiagnostic Systems, Boldon, UK).  142 
 143 
Micro-MRI 144 
MRI images of the proximal tibia with a resolution of 0.3mm x 0.3mm x 0.3mm were 145 
acquired with a 3T MRI scanner (Siemens Verio, Erlangen Germany) using a 146 
transmit/receive extremity coil which was suitable for knee imaging. The method used 147 
has been described previously (16) but briefly, the images were acquired from the right 148 
proximal tibia using the epiphyseal growth plate as a reference, with the first slice 149 
positioned immediately distal to the growth plate and subsequent slices positioned distally 150 
along the tibia. Standardized analysis was performed using the slice that was located at 151 
the insertion point of the patellar ligament. The images (Fig.1) were coded and analysed 152 
blindly using software written in IDL (Research Systems Inc, Boulder, CO) to obtain 153 
measures for apparent bone volume to total volume ratio (appBV/TV), apparent 154 
trabecular number (appTbN), apparent trabecular thickness (appTbTh) and apparent 155 
trabecular spacing (appTbSp). The analysis for each subject was repeated 4 times and 156 
averaged. In 29 out of 30 cases and in 27 out of 28 control participants, the images were 157 
of a sufficiently good quality to be analysed. Validation of the software was performed 158 
using a custom-made phantom, which consisted of a cylinder containing two discs with a 159 
parallel arrangement of nylon strings – 0·4-mm diameter string was used in one disc and 160 
0·2-mm diameter string in the other. In both cases, the strings were split into three regions 161 
 7 
with different spacings in each – 0·5, 1·0 and 1·5 mm. The phantom was filled with a 162 
NiSO4 solution to ensure adequate signal surrounding the strings, in a similar way to soft 163 
tissue surrounding bone. Due to partial volume effects and the similar magnitude of the 164 
resolution of the micro-MRI sequence to the thickness of the strings, the exact thickness 165 
of the strings could not be measured, and hence, the calculated bone parameters were 166 
expressed as ‘apparent’ values. The phantom validation allowed an optimal assessment of 167 
the effect of string thickness and string spacing on the apparent values. An assessment of 168 
repeatability was performed by one operator who independently analysed ten datasets 169 
four times each. 170 
 171 
MRS 172 
1H-MRS was performed using a 6-channel body array (anterior) and a 12-channel spine 173 
coil (posterior).  Spectra were obtained from a 20mm x 20mm x 20mm volume within the 174 
vertebral body of L3, using a method which has been described previously (16). Analysis 175 
was performed following fitting of the spectrum in the time domain using a nonlinear 176 
least-squares algorithm, AMARES (17) in the Java-based magnetic resonance user 177 
interface (jMRUI) software package (18). The area under the water peak and lipid peak 178 
(Fig.2) were obtained and used to calculate the lipid to water ratio (LWR), then 179 
percentage fat fraction (%FF) was calculated using the following equation (19): 180 
 181 
MRS data were available in all 30 cases and 28 controls.  182 
 183 
MRI of abdominal fat  184 
Of the participants who had MRS scans, in 24 cases and 19 controls, approval was also 185 
obtained to assess abdominal fat during the same scanning session using the 6-channel 186 
body array and the 12-channel spine coil. A T1 weighted turbo-spin-echo sequence was 187 
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used to acquire 5 axial slices at the level of L3 with a 4 mm slice thickness using the 188 
following parameters: (TR) Repetition Time 300ms,  (TE) Echo Time 11ms, (TA) 189 
Acquisition Time 17.2s, matrix size=288x320, with 255×340 mm field of view. The 190 
images were analysed with Slice-O-matic™ (version 4.3, Tomovision, Canada) for semi-191 
automatic measurement of cross-sectional area (CSA), subcutaneous adipose tissue, 192 
(SAT), visceral adipose tissue (VAT) and total adipose tissue (TAT).  193 
 194 
Calculation of Sample Size & Statistical Analysis 195 
The primary hypothesis in the study was that cases with T1DM would have a lower 196 
appBV/TV and appTbN and a higher appTbSp compared to controls. Based on recent 197 
studies from our group (16), the estimated CV of the microMRI measurements was less 198 
than 5%. To show a 10% difference between case and controls with a significant 199 
difference at p<0.05 with a power of 0.8, at least 16 cases and 16 controls were required 200 
for the above microMRI parameters. Data analysis was performed using XLSTAT 201 
v2013.3.01  (Addinsoft, Paris, France). All data were described as medians and ranges; 202 
comparison between the cases and controls was performed, initially by the Mann-Whitney 203 
U test for continuous variables and by the Chi Squared test for categorical variables and 204 
then subsequently adjusted for multiple comparisons using False Discovery Rates (FDR) 205 
(20).  Univariate analysis between continuous variables was performed using the Pearson 206 
correlation coefficient. 207 
 208 
 209 
 210 
Results 211 
Clinical Characteristics  212 
There were no significant demographic or anthropometric differences between the cases 213 
and controls (Table 1). Notably, the median BMI in the cases and controls was 24.8kg/m2 214 
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(18.2, 31.2) and 22.9kg/m2 (18.3, 33.9), respectively (p=0.1) with similar amounts of 215 
physical activity reported in the cases and controls. Of the 30 cases and 28 controls, 9 216 
(30%) and 3 (11%) reported a history of traumatic fractures (p=0.07). In 2 cases, the 217 
fractures had occurred before the onset of diabetes and in the other 7 cases, the duration 218 
of diabetes at the time of the fracture ranged between 2.5yrs and 16yrs. The median 219 
duration of T1DM was 12.8yrs (7.9, 34.2) with a median age at diagnosis of 9.9yrs (0.5, 220 
15.0). Of the 30 cases, 7 were on twice-daily insulin injections, 6 were on three-daily 221 
injections and 17 were on four-daily injections. The median total daily insulin dose for 222 
body weight was 0.94 IU/kg/d (0.43, 1.52) and the median current HbA1C was 9.8% (5, 223 
16) equivalent to 84mmol/mol (31, 151). Of the 30 cases, 15 (50%) had retinopathy of 224 
which 12 had background retinopathy alone, 2 (7%) were being treated for hypertension, 225 
1 (3%) had neuropathy and gastroparesis and none had microalbuminuria. One of the 226 
cases had stable Crohn’s disease requiring sulfasalazine therapy only for two years prior 227 
to the study and two cases were on a stable dose of thyroxine for acquired 228 
hypothyroidism, one of three years duration and another of five years duration.  229 
 230 
Biochemical Markers of Bone Metabolism, Adiposity & GH/IGF-1 Axis   231 
Amongst the markers of bone metabolism, plasma 25OHD and CTX were significantly 232 
lower in cases compared to controls (Table 1). However, serum PTH and markers of bone 233 
formation were similar in both groups (Table 1). Amongst the markers of the GH/IGF-1 234 
axis, plasma IGF-1 and ALS were significantly lower in the cases compared to controls 235 
whilst IGFBP3 was similar in both groups (Table 1). Plasma leptin was similar in the two 236 
groups and, as expected, showed a positive association to BMI (r,0.33; p=0.02) (Table 1). 237 
There was no association between HbA1c or the presence of retinopathy with the markers 238 
of bone metabolism, GH/IGF-1 axis or leptin.  239 
 240 
MRI of abdominal fat   241 
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Despite no significant differences in the BMI and plasma leptin between cases and 242 
controls, abdominal adiposity including CSA, VAT and TAT, was significantly higher in 243 
cases compared to controls (Table 2). However, SCAT was less markedly higher in cases 244 
and the difference did not reach statistical significance. Serum leptin did not show an 245 
association to any of the MRI-based markers of abdominal obesity. In addition, there was 246 
no association between adiposity with markers of control, markers of bone metabolism, 247 
GH/IGF-1 axis or leptin. 248 
 249 
Bone Microarchitecture by Micro-MRI 250 
Comparison of bone microarchitecture variables revealed that appBV/TV and appTbN 251 
were significantly lower and appTbSp significantly higher in cases compared to controls 252 
(Table 2). AppBV/TV and appTbN did not show any association to any biochemical 253 
markers or MRI-based markers of abdominal obesity. However, appTbSp showed a 254 
significant inverse association to serum ALS (r=-0.30, p=0.04) and OC (r=-0.38, p=0.009) 255 
(Fig.3). This inverse association was not observed between appTbSp and uOC. An 256 
inverse association was also suggested between appTbSp and serum IGF-1 but this did 257 
not reach statistical significance (r=-0.27, p=0.06).  In the T1DM cases, there was no 258 
association of appBV/TV, appTbN or app TbSp with HbA1c, age at diagnosis, duration of 259 
T1DM or daily insulin dose corrected for weight. However, there was a clear difference in 260 
median appBV/TV between those cases who had retinopathy and who did not have 261 
retinopathy. The median appBV/TV was 0.285 (0.22, 0.33) in those cases with 262 
retinopathy compared to 0.33 (0.25, 0.37) in those cases without retinopathy (p=0.02) 263 
(Fig.4). The HbA1c was 9.5% (5, 16) and 9.2% (5.5, 13) in the cases with and without 264 
retinopathy (NS). 265 
 266 
Bone Marrow Adiposity 267 
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Median vertebral BMA, expressed as percentage fat fraction (%FF), was higher in cases 268 
than controls but this did not reach statistical significant difference (Table 2). Vertebral 269 
BMA tended to show a positive association to VAT (r=0.3, p=0.051) which, as stated 270 
earlier, was higher in cases compared to controls (Table 2). There was no association 271 
between vertebral BMA and markers of GH/IGF-1 axis or bone turnover. Median BMA 272 
was 30.5% (9.9, 59.9) in those cases with retinopathy compared to 31.6% (11.3, 50.1) in 273 
those cases without retinopathy (p=0.97). 274 
 275 
 276 
 277 
 278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
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 288 
 289 
 290 
 291 
 292 
 293 
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Discussion 295 
The current study was primarily aimed at using MRI to compare the trabecular 296 
microarchitecture in young women with childhood-onset T1DM with that in healthy age-297 
matched women and is the first published clinical study to clearly show that this is altered 298 
in the former with reduced bone volume and trabecular number and increased trabecular 299 
separation. In addition, the study has also provided some insights into the underlying 300 
mechanisms that may lead to abnormality of skeletal development in adults with T1DM.  301 
 302 
In keeping with other reports of a higher prevalence of vitamin D deficiency in young 303 
people with T1DM, the women who participated in this study had lower vitamin D levels 304 
than the control group (21, 22). However, these levels were not particularly low and were 305 
not associated with a raised PTH or any other marker of bone formation or bone 306 
microarchitecture and it is, therefore, unclear whether the the lower vitamin D levels had 307 
a particularly marked contributory role. It is also unlikely that the women with T1DM had 308 
any other underlying genetic bone disorder as none had been revealed on history and 309 
examination. The reported rate of fractures in these cases seemed higher but not 310 
significantly different to controls and within the expected frequency for self-reported 311 
fractures in healthy women (23).  312 
 313 
The findings in the current study suggest that the deficits in bone microarchitecture that 314 
were encountered in T1DM may have a multifactorial aetiology. Firstly, the negative 315 
association between total osteocalcin, a marker of bone formation and trabecular 316 
separation in the study participants suggests that the osteopathy in T1DM may be linked 317 
to reduced bone formation rather than increased bone resorption. This was further 318 
reinforced by the lower levels of CTX, a marker of bone resorption, in the T1DM cases. 319 
This state of low bone turnover with reduced bone formation in T1DM has been reported 320 
previously (24, 25) and has been known to be associated with GH deficiency (26). To 321 
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facilitate recruitment, the current study did not stipulate fasting blood samples. Markers of 322 
bone turnover, and specially markers of bone resorption, such as CTX, show a diurnal 323 
variation and may be affected by fasting status (27) and future studies would benefit from 324 
standardisation of sample collection. 325 
 326 
The women with T1DM also had lower levels of circulating IGF-1 and ALS and the 327 
negative association of trabecular separation with ALS raises the possibility that the 328 
GH/IGF-1 axis and, in particular, reduced GH activity, may contribute to the altered bone 329 
microarchitecture. GH and IGF-1 are important regulators of bone homeostasis and 330 
important for the maintenance of bone mass (7). GH stimulates osteoblastic proliferation 331 
through stimulation of circulating and local IGF-1 and it inhibits adipogenesis (28). In 332 
humans, systemic availability of active IGF-1 is modulated through its binding to proteins 333 
such as IGFBP-3 and ALS (29), which, along with IGF-1, are primarily synthesized in the 334 
liver under the stimulation of GH (30). Insulin deficiency is reported to be associated with 335 
a state of GH resistance (31) an abnormality of post-translational synthesis of ALS and 336 
ALS deficiency (32, 33) and with lower levels of ALS, circulating IGF-1 falls due to 337 
increased renal clearance. As the insulin deficiency in the portal circulation exists despite 338 
insulin replacement in T1DM (34), it is likely that this state of GH resistance is not 339 
alleviated during treatment in T1DM and the abnormal bone findings in this study may be 340 
a consequence of a persistent state of IGF-1 and ALS deficiency. The finding in the 341 
current study of an inverse association between trabecular separation and serum 342 
osteocalcin and ALS reinforces this view. 343 
 344 
The other possible reason for the abnormality in bone microarchitecture in T1DM may be 345 
related to microvasculopathy. The clear association of reduced bone volume in those 346 
cases of T1DM who had retinopathy, albeit background retinopathy in most cases, 347 
suggests that it is possible that the underlying pathophysiology of retinopathy may also 348 
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influence trabecular development. The pathology of diabetic retinopathy evolves in an 349 
environment of increased formation of reactive oxygen species, leukostasis and 350 
breakdown of the blood-retinal barrier that is followed by formation of acellular 351 
capillaries and development of micro aneurysms (35). The superoxide generating family 352 
of NADPH oxidase enzymes have not only been strongly implicated in the vascular 353 
complications of diabetes but superoxide radicals may also be associated with 354 
abnormalities of bone turnover (36, 37). The possibility of a microvasculopathy that 355 
affects bone in T1DM has not been studied widely and requires further exploration.  356 
 357 
The women with T1DM in this study did not have a significantly higher BMI compared 358 
to controls but they had markedly higher visceral adiposity and it is possible that this 359 
abnormality is also associated with functional GH deficiency (38). Although bone marrow 360 
adiposity was similar in the cases and controls, the cases did have increased trabecular 361 
spacing which showed an inverse relationship to circulating ALS and osteocalcin. 362 
Increased trabecular spacing is not universally associated with increased bone marrow 363 
adiposity (15); whereas this association may be encountered in GH deficiency (16, 39), in 364 
other conditions such as osteogenesis imperfecta, the two parameters do not show an 365 
association (16).  It is also possible that in states of GH resistance such as T1DM, bone 366 
marrow adiposity may be increased. The current study was not powered to detect 367 
significant differences in bone marrow adiposity between the cases and controls and it is 368 
possible that with a larger sample size this would also have been detected. The finding of 369 
an abnormality of bone microarchitecture and bone marrow adiposity would be consistent 370 
with a defect in bone marrow mesenchymal stem cell differentiation which leads to a net 371 
reduction in bone formation in favour of adipogenesis (40) and as previously described in 372 
streptozocin induced T1DM mice (41) as well as conditions that are associated with 373 
relative IGF-1 deficiency (8,42,43).  374 
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Finally, the current study highlights the objective versatility of MRI based techniques in 375 
identifying differences in relatively small cohorts. Although there is now sufficient 376 
supporting evidence for the use of MRI for assessing bone microarchitecture (44), with 377 
the greater availability of 3T MRI scanners, there is a need to standardise the analytical 378 
techniques so that the clinical utility of MRI in metabolic conditions that are associated 379 
with abnormalities of bone health can be realised. With technological advances in 380 
hardware as well as analytical tools, an improvement in the current limited resolution of 381 
MRI as well as its ability to study cortical structure is highly likely. We chose to study 382 
young women only, primarily because they are more likely to develop osteoporosis in the 383 
long-term and to avoid the confounding effects of sex hormones but given that the 384 
increased fracture incidence has been encountered in both sexes and bone marrow 385 
adiposity increases with old age (45, 46), there is a need to study older as well as younger 386 
people with diabetes in both sexes. We did not perform DXA in this group but there is a 387 
need in future studies to assess the relationship of microMRI findings to DXA BMD as 388 
well as DXA based methods of assessing trabecular architecture (47). Given that hip 389 
fractures are reported to be commoner in people with T1DM (1,2,11), there is a place to 390 
examine the microarchitecture at this site too. The women with T1DM in this current 391 
group had a relatively high HbA1c and as expected for a population sample from an inner 392 
city area in the west of Scotland (48). A relationship between HbA1c and the bone 393 
parameters was not observed in the current study and perhaps this investigation would 394 
have been facilitated if there was a wider range of HbA1c. The lack of a relationship of 395 
the bone findings with HbA1c also raises the need to investigate the association with 396 
additional markers of glycation such as pentosidine (49). The lack of a sufficient number 397 
of cases with other complications associated with microvasculopathy limited the 398 
investigation of this association in the current study. The relationship between bone 399 
pathology and Type 2 DM is less clear with a lower risk of fractures (3). However, a 400 
recent study that examined bone marrow adiposity in women with Type 2 DM did report 401 
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a higher level of vertebral bone marrow adiposity in those who had a history of a fracture 402 
(50).  403 
 404 
In summary, detailed MRI studies in young women with T1DM have shown clear 405 
abnormalities of bone health that are characterised by reduced trabecular bone volume 406 
and reduced trabecular numbers. Possible underlying mechanisms that require further 407 
exploration include a microvasculopathy and GH resistance. 408 
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Legend To Figures 588 
 589 
Figure 1 Representative coronal 3T MR image of the proximal tibia. (A) showing 590 
 the placement of the reference line and the region of interest captured in 591 
 the axial images. (B) Micro-MR images. (C) Semiautomatic segmentation 592 
 delineates the trabecular bone compartment. (D) The region of interest 593 
 (ROI) is binarised to produce an image of a pure bone phase and a pure 594 
 marrow phase. (E) Higher magnification view of section within the ROI. 595 
 (F) A 3-D reconstruction of the trabecular bone within the ROI. 596 
 597 
Figure 2 Typical 1H-magnetic resonance spectrum of vertebral body L3. Bottom 598 
panel: original data. Middle panel: estimated spectrum fit as performed by 599 
the Java based Magnetic Resonance User Interface (jMRUI) software 600 
package. Top: individual peak components as fitted with jMRUI. Peak 601 
definitions are: 1 – water; 2 – lipid.  602 
 603 
Figure 3 The relationship between apparent trabecular separation (appTbSp) as 604 
assessed by MRI and serum acid labile subunit (ALS, panel A) and serum 605 
osteocalcin (OC, panel B) in women with T1DM (filled circles) and 606 
controls (open circles). A Gaussian ellipse of the data has been added to 607 
each plot, together with the correlation (r) and its p-value (p). An inverse 608 
association between appTbSp and ALS and OC was observed. 609 
 610 
Figure 4 Apparent bone volume/total volume (appBV/TV) in women with T1DM 611 
with and without retinopathy and compared to control women (open 612 
circles). 613 
 614 
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 615 
  T1DM Controls   
N 30 28 p 
Age (yrs)                                                                                                                       
BMI                                                                 
Cigarette smoker (n) 
Regular alcohol consumption (n) 
Ca, Vit D, Multivit supplements (n) 
Age at menarche (yrs) 
Previous pregnancy (n) 
Oral contraceptive use (n) 
Physical activity (hrs/wk) 
22.0 (16.9, 36.1)
24.8 (18.2, 31.2) 
4 
25 
4 
12 (10, 17.5) 
3 
21 
4 (0, 10) 
21.8 (18.6, 37.5) 
22.9 (18.3, 33.9) 
0 
27 
                6 
13 (11, 15) 
1 
22 
4 (0, 10) 
0.7 
0.1 
0.05 
 
 0.9 
 
 0.8 
 
 0.6 
 
 0.3 
 
 0.9 
 
 0.9 
PTH (pmol/l)  3.4 (1.1,9) 4.2 (1.4,12.5) 0.3 
25OH D (nmol/l) 33 (19, 65) 45.5 (25, 84) 0.02 
OC (µg/l) 13.4 (3.6, 20.8) 14.3 (6.6, 40.5) 0.2 
uOC (ng/ml) 1.8 (0.5, 13.9) 3.3 (0.5, 25.3) 0.18 
Bone ALP (U/l) 16.2 (10.5, 44.3) 17.2 (4.6, 28.8) 0.9 
CTX (µg/l)   0.15 (0.03, 0.39) 0.20 (0.05, 0.49) 0.04 
IGF-1 (µg/l) 135.2  (66.5, 83.1) 182.4 (83.1, 293.4) 0.002 
IGFBP-3 (µg/l)  2208 (1794, 3677) 2347 (1991, 3538) 0.17 
ALS (mU/ml) 2064 (1005, 3009) 2549 (1929, 3682) <0.0001 
Leptin (µg/l) 12.4 (1.3, 105) 14.3 (2.6, 43.3) 0.96 
 
Table 1 – Clinical and biochemical details of study participants. All continuous variables are described as 
median and range. PTH, Parathyroid hormone; OC, osteocalcin; uOC, undecarboxylated osteocalcin; 
25OHD, 25-hydroxyvitamin D; ALP, Alkaline phosphatase; CTX, crosslinked C-terminal telopeptides of 
type I collagen; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding protein 
3; ALS, acid labile subunit. Significance is assigned at p<0.05. 
 
 Table 2 MRI-based measures of abdominal adiposity, bone microarchitecture and vertebral 
bone marrow adiposity at L3. All data are described as median and range. CSA- cross-
sectional area of adipose tissue; SCAT – subcutaneous adipose tissue; VAT- visceral adipose 
tissue; TAT – total adipose tissue; AppBV/TV – apparent bone volume/total volume; 
AppTb.N – apparent trabecular number; AppTbSp – apparent trabecular separation; 
AppTbTh – apparent trabecular thickness. P-values have been adjusted for multiple 
comparisons using False Discovery Rates; significance has been assigned at adjusted p<0.05. 
 
 T1DM Controls P* 
 
N 30 
 
28  
CSA (mm2)  47,878 
(30,134, 78,651) 
 
39,918 
(30,232, 69,789) 
0.03 
SCAT (mm3) 21,583 
(3,719, 42877) 
 
15,582 
(7,454, 40,807) 
0.068 
VAT (mm3) 5,733 
(2,030, 11,144) 
 
3,460 
(1,808, 6,832) 
0.012 
TAT (mm3) 27,230 
(6,584, 54,021) 
 
19,130 
(10,046, 47,639) 
0.03 
AppBV/TV 0.3 
(0.22, 0.37) 
0.33 
(0.26, 0.4) 
0.018 
    
AppTb.N(mm-1)  0.26 
(0.2, 0.3) 
 
0.29 
(0.23, 0.3) 
0.012 
AppTb.Sp(mm)  2.59 
(2.24, 3.38) 
 
2.32 
(2.03, 2.97) 
0.012 
AppTbTh(mm)  1.14 
(0.86, 1.49) 
1.15 
(0.96, 1.39) 
 
0.3 
L3 fat fraction (%)  31.1 
(9.9, 59.9) 
 
26.3 
(8.5, 49.8) 
0.2 
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